The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
Open accessAbstract
We have shown that the proteasome inhibitor bortezomib (formerly known as PS-341) triggers significant antitumor activity in multiple myeloma (MM) in both preclinical models and patients with relapsed refractory disease. Recent studies have shown that unfolded and misfolded ubiquitinated proteins are degraded not only by proteasomes, but also by aggresomes, dependent on histone deacetylase 6 (HDAC6) activity. We therefore hypothesized that inhibition of both mechanisms of protein catabolism could induce accumulation of ubiquitinated proteins followed by significant cell stress and cytotoxicity in MM cells. To prove this hypothesis, we used bortezomib and tubacin to inhibit the proteasome and HDAC6, respectively. Tubacin specifically triggers acetylation of α-tubulin as a result of HDAC6 inhibition in a dose- and time-dependent fashion. It induces cytotoxicity in MM cells at 72 h with an IC 50 of 5–20 μM, which is mediated by caspase-dependent apoptosis; no toxicity is observed in normal peripheral blood mononuclear cells. Tubacin inhibits the interaction of HDAC6 with dynein and induces marked accumulation of ubiquitinated proteins. It synergistically augments bortezomib-induced cytotoxicity by c-Jun NH 2 -terminal kinase/caspase activation. Importantly, this combination also induces significant cytotoxicity in plasma cells isolated from MM patient bone marrow. Finally, adherence of MM cells to bone marrow stromal cells confers growth and resistance to conventional treatments; in contrast, the combination of tubacin and bortezomib triggers toxicity even in adherent MM cells. Our studies therefore demonstrate that tubacin combined with bortezomib mediates significant anti-MM activity, providing the framework for clinical evaluation of combined therapy to improve patient outcome in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAggresomes, inclusion bodies and protein aggregation
Kopito, R. R. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01852-3 · Cited by 1,921
Kawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A., & Yao, T.-P. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,524
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Self-citationHaggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
Self-citationMitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y.-T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1768 · Cited by 697
Self-citationMitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Akiyama, M., Hideshima, T., Chauhan, D., Joseph, M., Libermann, T. A., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00050-9 · Cited by 614
Self-citationMolecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N. C., Mitsiades, N., et al. (2003) · Blood · doi:10.1182/blood-2002-08-2543 · Cited by 566
Self-citationBennett, E. J., Bence, N. F., Jayakumar, R., & Kopito, R. R. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.021 · Cited by 509
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Self-citationUchiyama, H., Barut, B., Mohrbacher, A., Chauhan, D., & Anderson, K. (1993) · Blood · doi:10.1182/blood.v82.12.3712.3712 · Cited by 418
Self-citationHideshima, T., Chauhan, D., Schlossman, R., Richardson, P., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204623 · Cited by 394
Self-citationHassles with Taking Out the Garbage: Aggravating Aggresomes
Garcia‐Mata, R., Gao, Y., & Sztul, E. (2002) · Traffic · doi:10.1034/j.1600-0854.2002.30602.x · Cited by 391
Marks, P. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00084-5 · Cited by 344
Gregory, W. M., Richards, M. A., & Malpas, J. S. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.334 · Cited by 338
Molecular sequelae of histone deacetylase inhibition in human malignant B cells
Mitsiades, N., Mitsiades, C. S., Richardson, P. G., McMullan, C., Poulaki, V., Fanourakis, G., Schlossman, R., Chauhan, D., Munshi, N. C., Hideshima, T., et al. (2003) · Blood · doi:10.1182/blood-2002-11-3514 · Cited by 294
Self-citationBlockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
Chauhan, D., Li, G., Shringarpure, R., Podar, K., Ohtake, Y., Hideshima, T., & Anderson, K. C. (2003) · PubMed · Cited by 252
Self-citationCatley, L., Weisberg, E., Tai, Y.-T., Atadja, P., Remiszewski, S., Hideshima, T., Mitsiades, N., Shringarpure, R., LeBlanc, R., Chauhan, D., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0233 · Cited by 216
Self-citationHaggarty, S. J., Koeller, K. M., Wong, J. C., Butcher, R. A., & Schreiber, S. L. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00095-4 · Cited by 201
Self-citationCombination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
Raje, N., Kumar, S., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C., Podar, K., Le Gouill, S., Richardson, P., Munshi, N. C., et al. (2004) · Blood · doi:10.1182/blood-2004-06-2281 · Cited by 187
Self-citationHideshima, T., Chauhan, D., Hayashi, T., Akiyama, M., Mitsiades, N., Mitsiades, C., Podar, K., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207170 · Cited by 164
Self-citationVEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis
Gouill, S. L., Podar, K., Amiot, M., Hideshima, T., Chauhan, D., Ishitsuka, K., Kumar, S. K., Raje, N. S., Richardson, P. G. G., Harousseau, J., et al. (2004) · Blood · doi:10.1182/blood-2004-05-1760 · Cited by 155
Self-citationp38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells
Hideshima, T., Podar, K., Chauhan, D., Ishitsuka, K., Mitsiades, C. S., Tai, Y., Hamasaki, M., Raje, N. S., Hideshima, H., Schreiner, G. F., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1208118 · Cited by 139
Self-citationStructural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity
Wong, J. C., Hong, R., & Schreiber, S. L. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0341440 · Cited by 115
Self-citationNovel therapeutic approaches for multiple myeloma
Hideshima, T., Richardson, P. G. G., & Anderson, K. C. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00053.x · Cited by 90
Self-citationHideshima, T., Chauhan, D., Hayashi, T., Podar, K., Akiyama, M., Mitsiades, C. S., Mitsiades, N., Gong, B., Bonham, L., de Vries, P. W., et al. (2003) · PubMed · Cited by 67
Self-citation
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Metadata
- Authors
- Hideshima, T., Bradner, J. E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S. L., & Anderson, K. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-06-03
- Volume
- 102
- Issue
- 24
- Pages
- 8567-8572
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2166427186
- Cited by
- 593
- References
- 30
- FWCI
- 20.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.